Biden administration calls for expanded contraception coverage
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Less than 14 months after becoming a standalone company, Johnson & Johnson’s consumer healthcare spinout Kenvue is staring down an activist investor. The investor, Starboard
BETHESDA, MD — The FDA is rolling out a new six-month pilot program to provide more transparency to generic drug applicants on complicated regulatory issues,
As the radiopharma space heats up, CDMO Nucleus RadioPharma is expanding its commercial manufacturing with two new facilities to cater to potential clients outside North
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Nurix Therapeutics’ BTK degrader has elicited responses in a small group of patients with certain cancers, supporting the biotech’s claim that the drug could potentially
Plus, news about Takeda, Foresee Pharmaceuticals and Capricor Therapeutics: GSK, Cambridge University team up on immune diseases: The UK drugmaker is pouring £50 million …
Some, though certainly not all, chief indicators of biotech business activity are pointed shakily north as we head into a critical Q4. But biotech shows